BioCentury
ARTICLE | Clinical News

REP 2139-Ca: Interim Phase II data

May 11, 2015 7:00 AM UTC

Interim data from the open-label, Moldovian Phase II REP 301 trial in patients with chronic HBV and HDV co-infection showed that once-weekly IV REP 2139-CA as monotherapy was well tolerated and led to...